Incorporating Added Therapeutic Benefit and Domestic Reference Pricing Into Medicare Payment for Expensive Part B Drugs
-
Published:2023-09
Issue:9
Volume:26
Page:1381-1388
-
ISSN:1098-3015
-
Container-title:Value in Health
-
language:en
-
Short-container-title:Value in Health
Author:
Anderson Kelly E.,DiStefano Michael J.,Liu Angela,Mattingly T. Joseph,Socal Mariana P.,Anderson Gerard F.
Funder
Agency for Healthcare Research and Quality
Centers for Medicare and Medicaid Services
Arnold Ventures
Subject
Public Health, Environmental and Occupational Health,Health Policy
Reference18 articles.
1. Prescription drug spending in fee-for-service Medicare, 2008-2019;Dusetzina;JAMA,2022
2. A decade of increases in Medicare part B pharmaceutical spending: what are the drivers?;San-Juan-Rodriguez;J Manag Care Spec Pharm,2021